Your session is about to expire
← Back to Search
Abemaciclib for Brain Cancer
Study Summary
This trial is testing a new drug to see if it can help people with a specific type of brain tumor.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My oligodendroglioma has worsened after radiation and chemotherapy.I do not have an active infection or HIV, and my hepatitis is not currently active.My liver tests are within the required range for the study.I am not pregnant or breastfeeding.I am not currently using any other cancer treatments or investigational drugs.I have waited the required time after my last cancer treatment before joining this trial.I had surgery for cancer recurrence but still have visible disease.I've had treatments for cancer relapses and possibly surgery, but still have measurable cancer.I am not pregnant, can take a pregnancy test, and will use birth control during and after treatment.I agree to use birth control and not donate sperm for 3 months after my last dose.My blood counts meet the required levels for treatment.I have had treatments for multiple relapses of my condition.My tumor is a type of brain cancer called oligodendroglioma with specific genetic features.My liver is functioning well, based on recent tests.My blood counts meet the required levels for treatment.My kidney function is within the required range for the study.My oligodendroglioma has worsened after radiation and chemotherapy.I do not have severe lung problems, major stomach surgery, Crohn's, ulcerative colitis, or chronic severe diarrhea.I am 18 years old or older.I have recovered from serious side effects of my previous treatments.I can care for myself but may need occasional help.I can swallow pills.I have a history of serious heart rhythm problems or sudden cardiac arrest.I have been treated with a CDK4/6 inhibitor before.My kidney function is within the required range for the study.My tumor is confirmed as oligodendroglioma with 1p/19q codeletion.I have recovered from chemotherapy side effects, except for hair loss or mild nerve damage.I am not taking seizure medications like carbamazepine, phenytoin, or phenobarbital.
- Group 1: Single Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are people with the required qualifications able to join this trial at this time?
"Unfortunately, this study is not presently looking for new patients. The clinical trial was initially posted on May 15th, 2019 and was most recently edited on September 6th, 2022. However, there are 33 other trials actively enrolling patients with oligodendroglioma and 96 trials for Abemaciclib 200 MG that are still recruiting participants."
What are some of the illnesses that Abemaciclib 200 MG has been shown to improve?
"Abemaciclib 200 MG is most often used to treat patients with a high risk of recurrence. However, this medication can also be effective for managing advanced HR+HER2- breast cancer, endocrine therapy, and breast."
Has the FDA cleared Abemaciclib 200 MG for use?
"Abemaciclib 200 MG was given a safety score of 2. Phase 2 trials have shown some evidence of safety, but there is no data yet to support efficacy."
Share this study with friends
Copy Link
Messenger